San Donato (IT)
{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~26 mi. (Prato, Italy, +383 more cities)
facility
Nuovo Ospedale Di Prato
biomarker
ER Negative, +2 more biomarkers
condition
Breast Carcinoma
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
city
~26 mi. (Pisa, Italy, +122 more cities)
facility
A.O.U. Pisana
condition
Prostate Adenocarcinoma
drug
radium Ra 223 dichloride
drug type
radiation therapy
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
city
~26 mi. (Pisa, Italy, +260 more cities)
facility
Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2
biomarker
ERBB2 Amplification, +1 more biomarker
condition
Invasive Breast Carcinoma
drug
ado-trastuzumab emtansine, +1 more drug
drug type
immunotherapy, +1 more type
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~26 mi. (Pisa, Italy, +115 more cities)
facility
Azienda Ospedaliero Universitaria Pisana
biomarker
ERBB2 Amplification, +7 more biomarkers
condition
Breast Carcinoma
drug
ado-trastuzumab emtansine, +1 more drug
drug type
immunotherapy, +1 more type
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~26 mi. (Pisa, Italy, +137 more cities)
facility
Azienda Ospedaliero Universitaria Pisana ( Site 0603)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
city
~26 mi. (Pisa, Italy, +126 more cities)
facility
Azienda Ospedaliero Universitaria Pisana - Presidio Santa Chiara ( Site 0294)
condition
Adenocarcinoma of the Gastroesophageal Junction, +1 more condition
drug
FOLFOX regimen, +3 more drugs
drug type
chemotherapy, +2 more types
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~26 mi. (Pisa, Italy, +151 more cities)
facility
GSK Investigational Site
condition
Non-Small Cell Lung Carcinoma
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
city
~26 mi. (Pisa, Italy, +126 more cities)
facility
Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico
biomarker
ALK Fusion, +4 more biomarkers
condition
Malignant Solid Tumor
drug
entrectinib
drug type
targeted therapy